Drugs.com

NOVEMBER 9, 2023

9, 2023 -- The best way to prevent cervical cancer in women is to give HPV vaccines to both boys and girls, a new study argues. That way, herd immunity could help eradicate the cancer-causing virus, researchers say. THURSDAY, Nov. Cancer-related.

Virus 263

Virus Vaccine Research 263

Drug Target Review

AUGUST 11, 2023

In a new development, a recent paper published in Biology Methods & Protocols by Oxford University Press has highlighted a promising avenue for enhancing vaccine efficacy against infectious pathogens like the COVID-19 virus. Since December 2019, SARS-CoV-2 (COVID-19) infection has become a worldwide urgent public health concern.

Vaccine 98

Vaccine Immune Response Bioinformatics Virus 98

DrugBank

MARCH 12, 2025

The COVID-19 pandemic brought mRNA to global prominence by developing highly effective vaccines by Moderna and Pfizer-BioNTech. However, mRNA technology has introduced new possibilities, particularly in developing personalized cancer vaccines and combination therapies.

Vaccine 97

Vaccine Treatment Clinical Trials Therapies 97

DrugBank

JULY 18, 2024

Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. Yet, the recent COVID-19 pandemic highlighted the obstacles that are inherent today in the development of vaccines. Stabilizers play a crucial role in maintaining the vaccine's potency and integrity throughout its shelf life.

Vaccine 98

Vaccine Immune Response Clinical Trials Disease 98

Chemical Biology and Drug Design

SEPTEMBER 24, 2023

Moreover, these compounds treat influenza A virus through targets TLR4, TNF, IL6, MAPK1, MAPK3, IL1B, CASP3, AKT1, and EP300. Abstract Influenza virus continually challenges both human and animal health. In a certain degree, vaccines may not catch up with rapid mutant paces of viruses.

Virus 100

Virus Protein Expression Vaccine Research 100

Drugs.com

JULY 16, 2024

TUESDAY, July 16, 2024 -- People's odds for Long COVID appear to be declining with the advent of new variants of the virus, along with repeat infections and vaccinations, new research shows.That suggests that the average person's chances of.

Virus 130

Virus Vaccine Research 130

SCIENMAG: Medicine & Health

DECEMBER 21, 2023

Researchers have identified a previously unrecognized class of antibodies—immune system proteins that protect against disease—that appear capable of neutralizing multiple forms of flu virus.

Virus 77

Virus Vaccine Disease Research 77

Eye on FDA

DECEMBER 10, 2020

Today the Food and Drug Administration will hold a meeting of the Vaccines and Related Biologics Advisory Committee (VRBAC) to consider the application for an Emergency Use Authorization (EUA) submitted by Pfizer/BioNTech for their investigative vaccine for COVID-19. After nearly 40 years, a vaccine still eludes us.

Vaccine 97

Vaccine FDA Virus Trials 97

The Pharma Data

AUGUST 27, 2020

Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . Each patient was given two 100 microgram doses of the vaccine 28 days apart. These antibodies were higher than those seen in people who had recovered from the virus.

Vaccine 90

Vaccine Immune Response Clinical Trials Virus 90

SCIENMAG: Medicine & Health

AUGUST 20, 2023

Research at a Glance: A Murdoch Children’s Research Institute-led review has found COVID-19 vaccines are effective against severe cases of the disease in children and adolescents.

Vaccine 75

Vaccine Virus Disease Research 75

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Vaccine 52

Vaccine Virus Immune Response Clinical Trials 52

Drug Target Review

JUNE 1, 2023

La Jolla Institute for Immunology (LJI), US, scientists demonstrated how antibodies obtained from a clinical study participant attach to the SARS-CoV-2 spike protein and neutralise the virus. In the new study, antibodies were obtained from a clinical studies volunteer who received two doses of the Moderna SARS-CoV-2 vaccine.

Virus 97

Virus Vaccine Immune Response Research 97

Drug Target Review

MARCH 26, 2024

In my role as Chief Business Development Officer at Osivax, my main challenge is taking the deep scientific work of our research & development team and simplifying it for various audiences Could you share an example of a specific project or research that you have worked on and the impact it has had in your field?

Vaccine 110

Vaccine Virus Immune Response Science 110

Codon

AUGUST 26, 2024

He also explains how they could be used to combat pandemics on “day zero,” well before vaccines are developed. After the outbreak ended, it took another three years for the first Ebola vaccine by Merck to be approved. Timelines for vaccine development are shrinking, but can it move even faster?

RNA 97

RNA Virus DNA Vaccine 97

SCIENMAG: Medicine & Health

JULY 24, 2023

A new paper in Biology Methods & Protocols, published by Oxford University Press, shows it may be possible to design vaccines that will induce a stronger immune response to infecting pathogens, such as the virus causing COVID-19.

Vaccine 60

Vaccine Bioinformatics Immune Response Virus 60

The Pharma Data

JANUARY 21, 2021

President Joe Biden has promised to re-energize the nation’s response to COVID-19, but one of his top pandemic advisors says that effort could be hamstrung by both the virus and the failings of the previous administration. Right now, the main focus is on helping distribute the vaccines, Osterholm said.

Vaccine 52

Vaccine Virus RNA Research 52

The Pharma Data

JULY 6, 2021

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes. These epitopes could then be used in a vaccine to train T cells, providing protective immunity.

Vaccine 52

Vaccine Virus Research Immune Response 52

Drug Discovery Today

MAY 10, 2021

LONDON - Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has signed a contract with Imperial College London, as part of a Wellcome Trust (..)

Clinical Trials 100

Clinical Trials Virus Vaccine Pharmaceuticals 100

Drug Target Review

DECEMBER 6, 2023

Dear readers, Welcome to this report on cancer research, where we explore the latest breakthroughs in cancer research. Chapter 2 explores immuno-oncology, emphasising the significance of robust T cells, the potential of cytokines IL-12 and IL-18, and the innovative use of CAR T-cell methods against the SARS-CoV-2 virus.

Research 64

Research Pharmacy Vaccine Laboratories 64

Broad Institute

MARCH 22, 2024

McAlpine March 22, 2024 Credit: Catherine Boush, Broad Communications Related news New method tracks gene expression in single cells over space and time Messenger RNA (mRNA) made its big leap into the public limelight during the pandemic, thanks to its cornerstone role in several COVID-19 vaccines.

Engineering 140

Engineering Protein Production RNA Vaccine 140

The Pharma Data

MAY 5, 2022

In animal studies that mimic human exposures, an investigational COVID vaccine designed to be taken orally not only protects the host, but also decreases the airborne spread of the virus to other close contacts. The study, led by Duke researcher Stephanie N. The human vaccine is designed to be taken as a pill.

Vaccine 52

Vaccine Disease Virus Science 52

The Pharma Data

JUNE 26, 2021

Early in the COVID-19 pandemic, scientists identified how SARS-CoV-2, the virus that causes COVID-19, gets inside cells to cause infection. All current COVID-19 vaccines and antibody-based therapeutics were designed to disrupt this route into cells, which requires a receptor called ACE2. The study is published June 23 in Cell Reports.

Virus 52

Virus Cell Biology Vaccine Research 52

The Pharma Data

MARCH 3, 2022

The FDA decision is informed by the results of the Phase 2b proof-of-concept study of RSVpreF (NCT04032093), a global, double-blinded, placebo-controlled study that assessed the safety and immunogenicity of RSVpreF in healthy pregnant women ages 18 through 49 years old, who were vaccinated between 28- and 36-weeks gestation, and their infants.

Virus 52

Virus Vaccine Clinical Trials Trials 52

The Pharma Data

JULY 8, 2021

People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of eight sites, including Salt Lake City. Those who unfortunately got COVID-19 despite being vaccinated were still better off than those who didn’t.”

Vaccine 52

Vaccine Virus Nurses Hospitals 52

BMG Labtech

MARCH 11, 2024

They are often the method of choice to detect or measure specific biological molecules (analytes) for diagnostics, drug discovery or fundamental research. Early beginnings ELISAs were first developed in the mid-1970s independently by two research groups. ELISAs can also be used to measure the antibody responses elicited by vaccines.

Vaccine 98

Vaccine Molecular Biology Laboratories Virus 98

The Pharma Data

JULY 28, 2021

There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., The seventh vaccine candidate is an inert protein subunit. and Troy Randall, Ph.D.,

Vaccine 52

Vaccine Virus Clinical Trials Science 52

The Pharma Data

AUGUST 9, 2021

Research by Lancaster University scientists to create a COVID-19 vaccine which can be administered through the nose has taken a significant step forward. The pre-clinical animal trials of the intranasal vaccine showed a reduction in both the impact of the disease itself and transmission of the virus.

Vaccine 52

Vaccine Virus Immune Response Disease 52

Codon

JANUARY 21, 2024

Today, refined versions of these human challenge studies have become standard practice in testing vaccines for vector-borne diseases (e.g., Human challenge trials were an indispensable part of the development of the malaria vaccine, R21/Matrix-M, endorsed by the World Health Organization last October.

Vaccine 121

Vaccine Trials Disease Treatment 121

The Pharma Data

SEPTEMBER 30, 2021

As one among the leading global vaccines companies, we still bring options which help protect people’s health round the world,” said Michael Greenberg, MD, MPH, Medical Head, Sanofi Pasteur North America. “We 4,5 The CDC recommends a primary dose of the MenACWY vaccine at 11-12 years old and a second dose at 16 years old. In the U.S.,

Vaccine 52

Vaccine Research Virus Disease 52

The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. The samples were stored after the researchers measured the T cell response.

Virus 52

Virus Immune Response Vaccine Research 52

The Pharma Data

JANUARY 11, 2021

11, 2021 — As the rollout of the COVID-19 vaccines continues, scores of questions are emerging. How do the COVID-19 vaccines work? The COVID-19 vaccines work by teaching the immune system to protect against the virus, experts said. ” Can the vaccines make you sick? MONDAY, Jan.

Vaccine 52

Vaccine Virus DNA Doctors 52

The Pharma Data

APRIL 7, 2022

announced today that the companies have entered into a definitive agreement under which Pfizer will acquire ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV). NYSE: PFE) and ReViral Ltd.

Virus 52

Virus Vaccine Clinical Development Hospitals 52

The Pharma Data

JANUARY 21, 2021

Because the new COVID-19 vaccines should still work on these viral interlopers. Luckily, the new variants still rely on the coronavirus’ “spike protein” to infect cells, and the two COVID vaccines now on the U.S. This is a possibility why this virus seems to transmit more easily.” FRIDAY, Jan.

Vaccine 52

Vaccine Virus Immune Response RNA 52

Broad Institute

JANUARY 30, 2024

More bottles on the medicine shelf would help, but Bhattacharyya, who’s now also a research scientist, realized that science might lead to better tools for diagnosing and treating such challenging cases. TWO WHITE COATS Roby Bhattacharyya's mother, Maryka, visiting his graduate research lab at UCSF.

Hospitals 137

Hospitals Virus Medical Schools Science 137

The Pharma Data

JANUARY 11, 2021

Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday. based company has been in business for 10 years, but the COVID-19 vaccine was its first approved product. 18, 2020 ). It has already received $2.8

Vaccine 52

Vaccine Clinical Trials Virus RNA 52

The Pharma Data

DECEMBER 21, 2020

Army Researchers Analyze New Coronavirus Variant. military scientists to determine if it might be resistant to vaccines. The team at the Walter Reed Army Institute of Research is checking genetic sequences of the mutated virus variant posted online by British researchers, CNN reported. Professional. MONDAY, Dec.

Research 52

Research Vaccine Virus Disease 52

The Pharma Data

SEPTEMBER 30, 2021

That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. But now, we’re one step closer.

Vaccine 52

Vaccine Disease Immune Response Virus 52